INTRODUCTION {#S1}
============

Glioblastoma (GBM) is a devastating disease that afflicts \~15,000 Americans every year ([@R56]). The outcome of GBM patients remains extremely poor, despite aggressive surgery, chemotherapy, and radiation therapy. These tumors exhibit diffuse invasion into neighboring brain tissue and are not completely resectable without interfering with normal brain functions ([@R17]; [@R24]). The majority of GBMs recur locally within or adjacent to the radiated field ([@R1]; [@R66]). These residual cells develop alternative evolutionary paths that drive the growth of recurrent tumors and contribute to treatment failure ([@R36]; [@R76]). In fact, multiple studies have shown that a greater extent of resection is associated with improved survival in GBM ([@R12]; [@R38]; [@R39]; [@R65]).

Cancer stem cells contribute to recurrence in multiple cancer types, including GBM, but the exact mechanisms underlying such recurrence are unclear ([@R10]; [@R18]; [@R63]). Recently, we identified 2 distinct and mutually exclusive subtypes of patient-derived glioma stem-like cells (GSCs) that recapitulate either the proneural (PN) or the mesenchymal (MES) subtypes of GBM ([@R5]; [@R48]), suggesting that GSCs are heterogeneous. We and others have found subtype plasticity in both patient tumors and preclinical models ([@R2]; [@R5]; [@R37]; [@R48]), but what triggers this switch and how newly formed GSCs contribute to recurrence are unknown. Identifying the mechanisms of cancer stem cell plasticity in GBMs is crucial to understanding the cellular heterogeneity and molecular mechanisms that initiate recurrence ([@R27]; [@R50]).

Most primary GBMs are believed to have a PN origin, and single-cell sequencing studies ([@R58]) have shown that patients with a higher proportion of tumor cells with a PN signature have longer survival times than patients with mixed heterogeneous subtypes ([@R57]; [@R58]). Recent findings have reinforced the notion of plasticity among molecular subtypes of GBM upon recurrence, and the conversion to the MES subtype is associated with worse overall survival ([@R76], [@R77]). From these findings, we infer that the imminent conversion of PN GBMs to other subtypes, particularly MES, may provide a survival advantage to tumor cells. CD133, CD15, and other tumor initiation markers for GSCs ([@R40]) are not expressed in all tumors, such as MES GBMs ([@R5]; [@R48]), and markers for these GSCs have remained elusive. Furthermore, intratumoral heterogeneity and molecular subtype differences between GBM cells at the invading tumor edge and in the tumor core remain largely unexplored, and the molecular mechanisms that cause invading-edge cells to expand during recurrence are unknown.

CD109 is a glycosylphosphatidylinositol-anchored glycoprotein and is a member of the α2 macroglobulin/C3, C4, C5 family ([@R67]). Although CD109 is normally expressed on the surfaces of activated T cells, platelets, endothelial cells, and hematopoietic stem cells, its exact physiological roles are unknown ([@R28]). CD109 functions by binding to both transforming growth factor β1 (TGF-β1) and TGF-β receptor 1 (TGFBR1), thereby forming a macromolecular complex sequestered in caveolae and lipid raft compartments and eventually degrading the receptor complex and inhibiting SMAD signaling ([@R7]). High levels of CD109 have been reported in multiple cancers, including GBM ([@R16]; [@R29]; [@R64]; [@R69]; [@R80], [@R81]); notably, CD109^+^ circulating endothelial cells in recurrent GBM have been reported to be prognostic ([@R46]). However, the nature of the activation of CD109 in response to extrinsic signals and the modes by which it promotes tumorigenesis in GBM remain unknown. In a recent study using unbiased genomic approaches, CD109 was identified as a pro-metastatic gene in lung cancer ([@R16]). Rescue experiments, however, demonstrated that signal transducer and activator of transcription 3 (STAT3) activation, but not SMAD signaling, was required for metastasis. Thus, the differential regulation of TGF-β or STAT3 by CD109 appears to be context and tissue specific.

There is a gap in knowledge regarding (1) the mechanisms involved in the evolution of *de novo* or recurrent MES tumors from a PN precursor, and (2) the markers that can identify the cells responsible for recurrence in GBM. Understanding the mechanisms involved in PN-to-MES transition is crucial for designing therapeutic strategies for recurrent GBM. In this study, we defined the molecular features of tumor cells at the invading edge and in the core region, an objective complemented by the molecular profiling of longitudinal clinical specimens and functional characterization of these cells using clinically relevant models. Our results show that CD109 is an oncogenic driver of tumor initiation and radioresistance in GBM and identify an important molecular link between CD109, MES transition, and oncogenic yes-associated protein and transcriptional coactivator with a PDZ-binding domain (YAP/TAZ) signaling.

RESULTS {#S2}
=======

Discovery of Mutually Exclusive Populations of Tumor-Initiating Cells in GBM {#S3}
----------------------------------------------------------------------------

To compare the cellular and molecular signatures of tumor cells at the invading edge with those of cells in the tumor core, we used gene expression profile data from anatomically distinct regions of the tumor, available from the Ivy Glioblastoma Atlas Project (<http://glioblastoma.alleninstitute.org/>). Supervised clustering of transcripts representing either the PN, classical (CL), or MES subtype ([Table S1](#SD1){ref-type="supplementary-material"}; [@R73]) across tumor regions showed a clear trend of accumulation of the MES signature in the perinecrotic and pseudopalisading tumor regions (central core) and a predominant PN signature at the invading edge (leading edge; [Figure 1A](#F1){ref-type="fig"}). CL signatures were distributed between the 2 regions ([Figure S1A](#SD1){ref-type="supplementary-material"}).

Given the preferential expression of PN signatures in the invading edge, we performed a localized biopsy using a magnetic resonance imaging-guided neuronavigation system to collect tumor core tissue (within the enhancing portion of the mass on T1-gadolinium images) and tumor edge tissue (outside the enhancing portion of the mass but within the fluid-attenuated inversion recovery \[FLAIR\] change on T1-gadolinium images), followed by histopathological evaluation ([Figure 1B](#F1){ref-type="fig"}). A shortterm incubation of the collected tumor cells showed that *CD133*, a marker enriched in PN GSCs ([@R5]; [@R48]), was preferentially expressed in the tumor edge compared with the tumor core ([Figure 1C](#F1){ref-type="fig"}). In contrast to *CD133, CD109*---and less apparently *CD44*---were among the most upregulated genes in GSCs with an MES signature ([Figure S1B](#SD1){ref-type="supplementary-material"}). Both *CD109* and *CD44* were preferentially expressed in the tumor core compared with the tumor edge ([Figure 1C](#F1){ref-type="fig"}). Immunohistochemistry (IHC) using human GBM tissues revealed mutually exclusive patterns of CD109 and CD44 expression in the tumor core, as well as the expression of OLIG2, a surrogate marker of PN/CD133^+^ cells ([@R48]; [@R62]), in the tumor edge (Figures [1D](#F1){ref-type="fig"} and [S1C](#SD1){ref-type="supplementary-material"}). Analyses of an independent, freshly dissociated patient biopsy sample and a sample of patient-derived xenograft tissue from a mouse confirmed the mutually exclusive expression pattern of *CD133* and *CD109* ([Figures 1E and 1F](#F1){ref-type="fig"}). These data imply that CD133 and CD109 represent a mutually exclusive expression profile of PN and MES tumor cells localized in the tumor edge and core.

*In vitro* clonal neurosphere assays showed that CD109^+^ cells are more clonogenic and give rise to both CD109^+^ and CD109^−/low^ populations, whereas CD109^−/low^ cells had no or low CD109 expression, confirming that CD109^+^ cells are at the apex of stem cell hierarchy (Figures [1G](#F1){ref-type="fig"} and [S1D](#SD1){ref-type="supplementary-material"}). ALDH1A3, whose activity is a hallmark of cancer stem cells ([@R45]; [@R48]; [@R49]), was present almost exclusively in CD109^+^ cells but not in CD109^−/low^ cells (Figures [1H](#F1){ref-type="fig"} and [S1E](#SD1){ref-type="supplementary-material"}). In contrast, CD44, a pan-MES GBM marker, was detected in both cell populations ([Figure S1E](#SD1){ref-type="supplementary-material"}). *In vivo* tumorigenicity assays showed that in both freshly dissociated tumor cells and established GSCs CD109^+^ cells had greater tumor initiation capacity than CD109^−/low^ cells did ([Figure 1I](#F1){ref-type="fig"}). These tumors had the histopathological characteristics of high-grade glioma ([Figure 1J](#F1){ref-type="fig"}). These findings suggest that CD109 is preferentially expressed in the core GBM region distinct from CD133^+^ populations and retains stem cell and tumor-initiation properties.

CD109 Enrichment Is Associated with the MES Subtype and Worse Prognosis {#S4}
-----------------------------------------------------------------------

Using The Cancer Genome Atlas (TCGA) dataset, we found an overall higher expression of *CD109* in high-grade gliomas compared with low-grade gliomas and normal brains ([Figure 2A](#F2){ref-type="fig"}). *CD109* expression was higher in the MES subtype than in the PN or CL subtypes in the TCGA Agilent gene expression dataset ([Figure 2B](#F2){ref-type="fig"}). We analyzed the relation between *CD133/CD109* expression and tumor subtypes using 46 longitudinal GBM samples. In this dataset, *CD109* expression was highly associated with the MES subtype, and *CD133* downregulation or *CD109* upregulation was significantly associated with a recurrence as an MES but not PN or CL subtype (Figures [2C, 2D](#F2){ref-type="fig"}, [S2A, and S2B](#SD1){ref-type="supplementary-material"}). In both the Rembrandt and TCGA datasets, patients with the *CD109*^high^/*CD133*^high^ subtype had significantly shorter survival times (Figures [2E](#F2){ref-type="fig"} and [S2C](#SD1){ref-type="supplementary-material"}). These data were confirmed by IHC for CD109, demonstrating poorer prognosis in the CD109^high^ expression group ([Figures 2F](#F2){ref-type="fig"}).

IR Induces and Enriches CD109^+^ Cells {#S5}
--------------------------------------

We used microarray analysis to assess the molecular alterations in CD133^high^/PN GSCs (n = 2) at various time points after exposure to ionizing radiation (IR) ([@R48]). Irradiated CD133^high^/PN GSCs clustered closely with CD109^high^/MES GSCs as early as 24 h after exposure to IR, whereas their untreated counterparts clustered as a distinctly separate group (Figures [3A](#F3){ref-type="fig"} and [S3A](#SD1){ref-type="supplementary-material"}). The most differentially expressed genes from this dataset clearly separated TCGA tumors into PN or MES subtypes ([Figure 3B](#F3){ref-type="fig"}), indicating that these gene clusters reflect the 2 major GBM subtypes. *CD109* was highly induced (by orders of magnitude) in PN GSCs in response to IR, whereas *CD133* was the marker with the lowest expression in these cells ([Figure 3C](#F3){ref-type="fig"}; [Table S2](#SD1){ref-type="supplementary-material"}). Western blotting revealed the absence of CD109 expression in CD133^high^/PN GSCs, confirming the mutually exclusive expression of the 2 markers and the prevalence of CD109 in MES GSCs ([Figure 3D](#F3){ref-type="fig"}). Validating these results using qPCR analysis showed the rapid switch of *CD133* to *CD109* expression following IR of CD133^high^/PN GSCs ([Figure 3E](#F3){ref-type="fig"}). This change in expression was accompanied by a reduction of *OLIG2* and a concomitant induction of a panel of MES markers, including *CD44*, as detected by qPCR and immunofluorescence analyses in both *in vitro* and *in vivo* systems ([Figures S3B-S3D](#SD1){ref-type="supplementary-material"}).

To determine whether the IR-induced changes in CD133 and CD109 expression could be a secondary enrichment of CD109^+^/CD133^−^ cells or the result of a direct reprogramming of CD133^+^/CD109^−^ GSCs into CD133^−^/CD109^+^ GSCs, we conducted *in situ* hybridization experiments using molecular beacon probes. Live monitoring of *CD133* and *CD109* at the single-cell level revealed the emergence of CD109 expression in CD133^+^ but not CD133^−^ cells after exposure to IR ([Figure 3F](#F3){ref-type="fig"}). The induction of CD109 expression in CD133^+^ but not CD133^−^ cells was directly captured by clonal tracking of irradiated GSCs (Figures [3G](#F3){ref-type="fig"} and [S3E](#SD1){ref-type="supplementary-material"}; Videos [S1](#SD4){ref-type="supplementary-material"} and [S2](#SD5){ref-type="supplementary-material"}). The lack of *CD109* induction in CD133^−^ cells was not due to cell death, as more than half of both populations were viable after sorting and IR ([Figure S3F](#SD1){ref-type="supplementary-material"}). Notably, a small set of the populations retained CD109 expression at levels similar to those of MES GSCs even 3 months after IR (Figures [3H](#F3){ref-type="fig"} and [S3C](#SD1){ref-type="supplementary-material"}). Thus, the IR-induced transition of GSC subtypes can be tracked by the cell surface markers CD133 and CD109.

*In vitro* analysis of GSCs that had transformed to a CD109^high^/MES subtype in response to IR (GSC157/R and GSC84/R) had higher clonogenicity ([Figure 3I](#F3){ref-type="fig"}), higher motility (Figures [3J](#F3){ref-type="fig"} and [S3G](#SD1){ref-type="supplementary-material"}), and higher levels of the MES marker CD44 ([Figure 3K](#F3){ref-type="fig"}). In secondary xenograft assays using GSC157/R, only the CD109^+^ fraction could form tumors in a subset of the mice, suggesting that CD109 is a marker of tumor initiation in GSCs that escape IR ([Figure 3L](#F3){ref-type="fig"}). In concordance with the radioresistant phenotypes associated with CD133^low^/CD109^high^ tumors, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses of recurrent tumors revealed the activation of DNA repair-related signatures, including mismatch repair, homologous recombination, nucleotide excision repair, and base excision repair in these tumors ([Figure S4](#SD1){ref-type="supplementary-material"}).

*CD109* Is Regulated by C/EBP-β in Response to IR in CD133^high^/PN GSCs {#S6}
------------------------------------------------------------------------

We next examined the mechanisms by which IR induces CD109 expression in GSCs. One of the earliest responses to IR-mediated DNA damage is ataxia telangiectasia mutated (ATM) activation ([@R6]), which can activate nuclear factor κB (NF-κB) via phosphorylation of the NF-κB essential modulator ([@R31]; [@R78]). Also, we and others have demonstrated that GSCs undergo MES differentiation, with the associated acquisition of radioresistance, in a tumor necrosis factor α (TNF-α)/NF-κB-dependent manner ([@R5]; [@R53]). Activation of NF-κB by both IR and TNF-α caused upregulation of *CD109* expression in an NF-κB-dependent manner ([Figure 4A](#F4){ref-type="fig"}). Using bioinformatic approaches ([@R11]; [@R43]; [@R70]), we found no predicted binding sites for the NF-κB subunits p65 or p50. Instead, we found 1 binding site each for STAT3 and CCAAT/enhancer binding protein β (C/EBP-β), the master regulators of the MES signature that act downstream of NF-κB ([Figure 4B](#F4){ref-type="fig"}) ([@R4]; [@R13]). *STAT3* and *CEBPB* expression was induced in GSCs as early as 6 h after IR ([Figure 4C](#F4){ref-type="fig"}), whereas *CD109* expression increased 24 h after IR, which suggests that STAT3 and/or C/EBP-β can be upstream regulators of *CD109*. Pretreatment with small interfering RNA (siRNA) against *STAT3* or *CEBPB* followed by IR showed that *CEBPB* but not *STAT3* is responsible for the IR-mediated induction of *CD109* ([Figure 4D](#F4){ref-type="fig"}). The chromatin immunoprecipitation assay using a specific antibody confirmed the recruitment of C/EBP-β to the *CD109* promoter in PN GSCs upon treatment with TNF-α or IR, as well as at baseline in MES GSCs ([Figure 4E](#F4){ref-type="fig"}). These results indicate that C/EBP-β is a direct transcriptional regulator of *CD109* in response to NF-κB activation by IR or TNF-α. Gene Ontology analysis identified a marked elevation of the wound repair pathways and upregulation of pro-inflammatory factors, including *CEBPB*, in irradiated CD133^high^/PN GSCs ([Figures 4F and 4G](#F4){ref-type="fig"}).

CD109 Plays an Essential Role in Clonogenicity, Tumor Initiation, and Radioresistance in GBM {#S7}
--------------------------------------------------------------------------------------------

Because CD109^+^ cells showed tumor-initiating potential, we postulated that these cells depend on CD109 for their self-renewal and growth. CD109 silencing in CD109^high^/MES GSCs was achieved with lentiviral infection using 2 independent small hairpin RNA (shRNA) constructs ([Figure 5A](#F5){ref-type="fig"}). Neurosphere assays demonstrated that CD109 silencing diminishes the number of clonogenic sphere-forming cells (1/143 in shCD109-2-infected cells versus 1/22.5 in non-targeting shRNA \[shNT\]-infected cells) in a dosage-dependent manner ([Figure 5B](#F5){ref-type="fig"}). These results were reproduced in 2 additional independent CD109^high^/MES GSCs ([Figure S5A](#SD1){ref-type="supplementary-material"}).

Radiation caused no significant differences in the neurosphere formation rates of the control cells, whereas shCD109 significantly reduced neurosphere formation after radiation ([Figure S5B](#SD1){ref-type="supplementary-material"}). Because they lack functional p53, most GSCs preferentially exhibit the activation of the G2/M but not the G1/S checkpoint ([@R5]; [@R30]). After irradiation, the G2/M population consistently was modestly increased in shNT-infected cells but strongly induced in shCD109-infected cells ([Figure 5D](#F5){ref-type="fig"}). We further examined H2AX phosphorylation (Ser 139), a marker of double-strand breaks, whose reduction reflects DNA damage repair ([@R22]). Silencing CD109 dramatically increased γ-H2AX in cells with reduced CD109 in response to IR, suggesting a defective DNA damage repair capacity in cells lacking CD109 ([Figure 5E](#F5){ref-type="fig"}). CD109 silencing substantially increased the proportions of annexin V^+^ and phosphatidylinositol-positive (PI^+^) cells in CD109^high^/MES GSCs and in GSC157/R, suggesting that CD109 protects GSCs from radiation-induced apoptosis (Figures [5F](#F5){ref-type="fig"} and [S5C](#SD1){ref-type="supplementary-material"}). *In vivo*, silencing CD109 reduced tumor formation latency (Figures [5G](#F5){ref-type="fig"} and [S5D](#SD1){ref-type="supplementary-material"}), which was further reduced upon IR ([Figure 5G](#F5){ref-type="fig"}), confirming the importance of CD109 for the tumor-initiating properties of CD109^high^/MES GSCs. We note that the specific influence of sex of the mice on outcomes was not analyzed, but mice of both sexes were randomized into experimental groups.

Evolutionarily Conserved Regulation of YAP/TAZ Activity by CD109 in Gliomagenesis {#S8}
---------------------------------------------------------------------------------

To delineate the molecular mechanisms by which CD109 regulates tumor propagation in GSCs, we performed gene expression profiling on shCD109-infected GSCs. We examined several conserved pathways that play essential roles in gliomagenesis. We have previously shown that the Hippo signaling transcriptional co-activator TAZ promotes MES transition in GSCs ([@R4]). In addition, CD109 and YAP/TAZ regulate some overlapping biological pathways in cancer ([@R29]; [@R44]; [@R60]). Therefore, we examined the expression of YAP/TAZ targets in shCD109- and shNT-infected CD109^high^/MESGSCs. Several of the YAP/TAZ-associated genes were downregulated in the shCD109-infected cells compared with the shNT-infected cells ([Figure 6A](#F6){ref-type="fig"}). Furthermore, gene set enrichment analysis showed positive enrichment of YAP/TAZ signaling in shNT-infected cells compared to shCD109 cells ([Figure 6B](#F6){ref-type="fig"}). Reduction of the YAP/TAZ transcriptional activity was confirmed by the suppressed luciferase activity of the synthetic TEAD reporter (8xGTIIC-Luc) ([@R20]) in shCD109-infected GSCs ([Figure 6C](#F6){ref-type="fig"}). YAP/TAZ targets *CTGF, CYR61*, and *ANKRD1* showed dramatically reduced expression, with a concomitant reduction of *CD44*, in shCD109-infected cells compared with control groups ([Figure 6D](#F6){ref-type="fig"}), suggesting that *CD109* regulates *YAP/TAZ* transcriptional activity. Western blotting showed a reduction of total and nuclear TAZ in shCD109-infected cells ([Figures 6E and 6F](#F6){ref-type="fig"}). Silencing CD109 also reduced the total levels of YAP ([Figure S6A](#SD1){ref-type="supplementary-material"}), which was modest compared to the reduction of S127 phosphorylation, suggesting that CD109 can regulate YAP/TAZ independently of the Hippo signaling pathway ([Figure S6A](#SD1){ref-type="supplementary-material"}). Reduced TAZ and YAP expression was also observed in long-term cultured GSC157/R upon silencing CD109 ([Figure S6B](#SD1){ref-type="supplementary-material"}). Cycloheximide chase experiments showed that silencing CD109 destabilized TAZ ([Figure S6C](#SD1){ref-type="supplementary-material"}). These experiments demonstrate that CD109 acts upstream of the YAP/TAZ signaling pathway, which could contribute to the stem cell and tumor-promoting properties of CD109^+^ tumor cells. Of note, in contrast to a previous report ([@R16]), CD109 silencing in GSCs did not reduce STAT3 expression ([Figure S6D](#SD1){ref-type="supplementary-material"}).

Although the re-expression of TAZ in shCD109-infected clones was not successful in long-term culture, rescue by the overexpression of a constitutively active form of TAZ, 4SA, in these clones was able to reduce the increased number of γ-H2AX foci seen in shCD109-infected cells in response to IR ([Figure S6E](#SD1){ref-type="supplementary-material"}). This was abolished upon the overexpression of a 4SA mutant (4SA-S51A) that impedes TAZ entry into the nucleus ([@R4]), indicating that at least the effect of CD109 on DNA damage repair capacity depends on nuclear TAZ. This is even more important, given the tight clinical correlation of *CD109* with both *YAP* and *TAZ* in human GBMs ([Figure 6G](#F6){ref-type="fig"}).

Finally, to assess the importance of CD109-driven YAP-TAZ signaling *in vivo*, we used a previously characterized *Drosophila* glioma initiation model and manipulated endogenous PI 3-kinase (PI3K) (*UASPten*^*RNA*^) and exogenous oncogenic Ras (*UASRas*^*V12*^) in the larval brain ([@R15]; [@R61]). This tumor-initiation model enabled us to directly introduce mutations of the Tep1 gene (the *Drosophila* CD109 ortholog) into *Drosophila* glial neoplasms and test their effects on Yki (the *Drosophila* YAP/TAZ ortholog) ([@R8]; [@R21]). Compared with wild-type larval brains, larval brains with Tep1 mutations had upregulated Yki expression during gliomagenesis *(repo* \> *GFP, Pten^RNAi^, Ras^V12^)* (Figures [6H](#F6){ref-type="fig"} and [S6F](#SD1){ref-type="supplementary-material"}). Genetic manipulation of Tep1 by RNA interference in normal glial cells (*repo \> Tep1*^*RNAi*^) showed only a mild decrease in Yki levels ([Figure 6H](#F6){ref-type="fig"}). In contrast, Tep1 elimination in glioma cells (*repo* \> *GFP, Pten^RNAi^, Ras^V12^, Tep1^RNAi^*) substantially reduced Yki and attenuated gliomagenesis *in vivo* ([Figure 6H](#F6){ref-type="fig"}). Next, we tested whether Tep1 downregulation affects Yki activity by examining the expression levels of a transcriptional target of YKi, the *Drosophila* inhibitor of apoptosis protein 1 (Diap1) ([Figure 6H](#F6){ref-type="fig"}) ([@R34]; [@R51]). Compared with wild-type larval brains, larval brains with Tep1 mutations had strongly induced Diap1 levels in glial neoplasms ([Figure 6H](#F6){ref-type="fig"}), whereas Tep1 downregulation resulted in Diap1 downregulation. These data suggest that Tep1 (CD109 in human) affects Yki (YAP/TAZ in human) levels and activity and that the genetic targeting of Tep1 reduces gliomagenesis *in vivo*, possibly owing to the reduced Yki levels and activity (Figures [6H](#F6){ref-type="fig"} and [S6G](#SD1){ref-type="supplementary-material"}). Furthermore, the redundancy of Tep1-Yki interactions in *Drosophila* and CD109-YAP/TAZ interactions in human reflects an evolutionarily conserved signaling axis in glioma initiation ([Figure S6H](#SD1){ref-type="supplementary-material"}).

DISCUSSION {#S9}
==========

In this study, we report 4 major findings: (1) the existence of mutually exclusive GSCs with tumor initiating properties in the tumor core versus the edge; (2) gain of CD109 in tumor cells at the edge in response to IR; (3) IR induced pro-inflammatory response transcriptionally regulates CD109 via C/EBP-β; and (4) CD109 drives oncogenic signaling through the YAP/TAZ pathway.

We and others have described the concept of PN-to-MES transition in GBM both under the influence of the microenvironment and IR ([@R5]; [@R26]; [@R41]; [@R48]). The cells that escape stress induced by radiation, in particular, represent a phenotypically robust sub-population that could be targeted. Here, we demonstrate that these cells can be identified using CD109, which is expressed in both *de novo* MES and cells in GSCs that undergo IR-mediated MES transition. We further extend these observations to patient populations and show that an MES recurrence is associated with an increase in CD109 expression. In support of our findings, CD109 has been shown to be associated with MES-like GBM ([@R71]), and a recent study proposed CD109 as a cancer stem cell marker with a preferential enrichment of CD109^+^ tumor cells in the perivascular niche in high-grade gliomas ([@R64]).

During surgical resection of GBMs, most of the T1 gadoliniumenhancing portion of the lesion is removed, whereas the non-enhancing tumor edge tissue within the T2/FLAIR abnormality is largely, if not completely, left behind. These unresectable residual cells at the invading edge have long been hypothesized to contain the seeds of recurrence. A recent study showed molecular differences between the enhancing lesion, the necrotic core, and the enhancing margin in post-surgical tissues and the existence of PN and MES GSCs in a spatially restricted manner ([@R33]). Nonetheless, these 3 portions of the tumor are largely resectable. In this study, we demonstrate that properties of the non-enhancing FLAIR regions (outside the enhancing region) may contain functional, eloquent brain areas that surround infiltrating, recurrence-initiating tumor cells. Our findings show that these regions of the brain are enriched with CD133^+^ PN tumor cells that exhibit a rapid and substantial gain of CD109 immediately after IR. Both IR-induced and treatment-naive CD109^+^ cells are highly tumorigenic, recapitulating high-grade glioma features in mouse brain xenografts. Moreover, we found that CD109^+^ GSCs are radioresistant and that functional characterization of these cells could lead to the identification of therapeutic targets for overcoming radioresistance in GBM. Despite endogenous induction of *CD109* in cells undergoing MES transition, it is noteworthy that the ectopic expression of CD109 in PN GSCs induced cell death (not shown). Although we are unable to pinpoint the exact reason for this observation, previous studies have demonstrated that the abrupt activation of MES regulators in epithelial cells has deleterious effects ([@R47]).

Another important facet of the present study is the molecular characterization of the mechanisms by which *CD109* is transcriptionally controlled and the downstream oncogenic pathways that are regulated by this protein. We found that IR promotes the activation of NF-κB and induction of C/EBP-β, which in turn directly binds to the *CD109* promoter to activate its transcription. Although CD109 appears to be regulated by proinflammatory mechanisms in GBM, studies with CD109 transgenic mice have revealed an anti-inflammatory role for CD109 ([@R74]), which suggests that CD109 alters pathways in a tissue- and context-specific manner. Furthermore, our expression profiling analyses revealed that silencing CD109 did not affect the TGF-β or STAT3 signaling pathways (not shown). To the contrary, we found that CD109 acts upstream of YAP/TAZ and that silencing CD109 dramatically alters YAP/TAZ signaling. How CD109 affects YAP/TAZ functions and whether YAP/TAZ downregulation is required for CD109 oncogenic signaling remain to be determined. Given that recent studies have shown a requirement of GP130 in CD109-mediated lung metastases ([@R16]) and that the GP130-Src-YAP axis is operational in inflammation ([@R68]), we speculate that CD109 may regulate YAP/TAZ by binding to GP130. Nevertheless, our finding that altering CD109/Tep affects YAP/TAZ/Yki expression and activity and glioma growth in human and *Drosophila* glioma models suggests an evolutionarily conserved mechanism.

Given that radiation- and CD109 expression-induced gene signatures are associated with poor clinical outcomes and that CD109 drives oncogenesis via YAP/TAZ, for which pharmacological targets are emerging ([@R79]), our findings may inform the development of individualized subtype-specific therapeutics for patients with MES GBM and other MES cancers in the near future.

STAR\*METHODS {#S10}
=============

CONTACT FOR REAGENT AND RESOURCE SHARING {#S11}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Dr. Krishna Bhat (<kbhat@mdanderson.org>).

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S12}
--------------------------------------

### *In vivo* animal studies {#S13}

One week after guide screw implantation, 5 × 10^5^ or fewer (as indicated) GSCs were randomly distributed among and injected intracranially into groups of 4- to 5-week old Foxn1^nu^mice. Littermates of the same sex (all females) were randomly assigned to experimental groups of 5 mice each. Mice were subjected to fractionated radiation at the intensity of 2.5 Gy for 4 consecutive days ([@R55]). All animal experiments were performed at The Ohio State University and MD Anderson Cancer Center under Institutional Animal Care and Use Committee --approved protocols according to NIH guidelines.

### Human studies {#S14}

Experiments involving human tissues were approved by The Ohio State University, MD Anderson Cancer Center, and University of Alabama at Birmingham Institutional Review Boards (approval \#2005C0075, \#LAB04-0001, \#N151013001, and \#N151014002). All studies involving human subjects were conducted after obtaining informed consent from the patients. Patient-derived specimens were provided to the corresponding scientists after de-identification of the original tumors. Because of the de-identification process, the information of the gender was not available. For the data downloaded from TCGA and IVY glioblastoma projects, data on gender of the patients is available online (<https://portal.gdc.cancer.gov/>;<http://glioblastoma.alleninstitute.org/rnaseq/search/index.html>).

### Cell lines {#S15}

Glioma spheres were established from 14 GBM patient samples (sample ID: GSC157, GSC84, GSC185A, GSC83, GSC267, GSC11, GSC20, GSC28, GSC23, GSC11, GSC1010, GSC1020, GSC1051, GSC1079) ([@R54]; [@R19]; [@R25]; [@R48]; [@R5]).

In brief, GSCs were isolated from patients undergoing surgery at Ohio State University (OSU), M.D. Anderson Cancer Center (MDACC) and University of Alabama at Birmingham (UAB) after de-identification. Because of the de-identification, the gender of the patients was unavailable. These cells were grown in neural basal medium (Dulbecco's Modified Eagle Medium \[DMEM\]/F12 50/50; Cellgro or GIBCO) supplemented with B27 (Invitrogen or Militenyi), 20 ng/mL EGF (Chemicon or PeproTech), and 20 ng/mL FGF (Akron-Biotech or PeproTech). Phenotypic characterization of these GBM-derived neurosphere cultures has been previously established ([@R5]; [@R52]; [@R32]; [@R48]). 293FT cell line was obtained from ATCC.

*DROSOPHILA* STOCKS {#S16}
-------------------

Transgenic *Drosophila* flies of the following genotypes (described in Flybase) were used: *repoGAL4 UAS-GFP/TM3, Sb* ([@R75]), *UAS-pten*^*RNAi*^ (BL\# 8548), *UAS-Ras*^*V12*^ ([@R35]), UAS-Tep1^RNAi^(BL\#32856), Tep1^MI04262^ (BL\# 37420), UAS-Tep3^RNAi^ (BL\# 56020), and Tep2^MI01299-GFSTF.2^ (BL\#59402). All *Drosophila* stocks and crosses were maintained at 25°C. Mutant and Transgenic *Drosophila melanogaster* stocks were maintained on standard cornmeal, molasses and agar medium. The genetic crossing scheme resulted in the induction of brain neoplasms (glioma) in both male and female larvae that showed no significant differences in glioma size, frequency or effects of Tep downregulation.

METHOD DETAILS {#S17}
--------------

### Viral infection {#S18}

293FT cells were co-transfected with the pLKO.1 vector encoding the shRNA and the helper plasmids for virus production (psPAX2 and pMGD2) using calcium phosphate. Lentivirus was harvested 72 h after transfection, concentrated 100-fold using a Lenti-X concentrator, and stored at −80°C until infection. Lentivirus infection was performed with polybrene according to the manufacturer's protocol. GSCs were infected with adenovirus expressing RFP and IκB-SR (Vector Biolabs) 48 h before irradiation or treatment with 10 μM TNFα. For the rescue experiment, shCD109-infected GSC20 cells were transduced with retroviral particles containing the pBABE vector expressing wild-type TAZ, 4SA, or 4SA-S51A. Forty-eight hours after infection, the cells were washed and selected in medium containing puromycin (4 μg/ml).

### siRNA transfection {#S19}

The transient knockdown of genes was performed using siRNA constructs targeting STAT3, C/EBP-β, or a non-targeting scrambled sequence. Cells were transfected with siRNAs using Lipofectamine 2000 according to manufacturer's recommendations. The final siRNA concentration was 60 nM. Cells were irradiated 48 h after siRNA transfection, collected, and analyzed 72 h later.

### RT-PCR {#S20}

Total RNA was extracted and purified using the QIAGEN RNeasy Mini Kit according to the manufacturer's instructions. RNA quality and concentration were determined using a Nanodrop. Total RNA (0.5-1 μg) was reverse-transcribed in cDNA that was then amplified by oligonucleotide genes specific via Sybr Green method or through taqman assay. The fluorescent signal was measured using the Viia7 Real-Time PCR software program and the relative fold changes were calculated using the absolute δδCt method.

### Western blot {#S21}

Proteins were extracted from GSCs using 0.5% NP-40 lysis buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, and 50 mM NaF supplemented with protease inhibitors and phenylmethylsulfonyl fluoride just before use. Protein concentrations were determined using the Bradford method. For the nuclear fractionation the cell pellet was resuspended in 1 mL of RSB buffer (0.01 M Tris--HCl, 0.01 M NaCl, 1.5 mM MgCl~2~, pH 7.4) and placed on ice for 10 min. Swollen cells were then collected by centrifugation at 1500 rpm for 8 min, and resuspended in 1 mL of RSB buffer containing 0.5% NP-40. Cell membranes were then broken using a Dounce homogenizer (tight pestle) by 10 up and down strokes. Nuclei (pellet) were collected by centrifugation at 1500 rpm for 8 min and resuspended in NP-40 with proteinase and phosphatase inhibitor (1:100) ([@R3]). Western blot analysis was performed using standard protocols.

### Immunohistochemistry and Immunofluorescence {#S22}

Paraffin-embedded human glioblastoma (GBM) specimens were obtained from the Institutional Tissue Bank at The Ohio State University and cut into 5-μm sections. Mouse brains were perfused with ice-cold phosphate-buffered saline (PBS) then fixed in 4% PFA for 24-48 h and transferred into 10% formalin. Paraffin-embedded tissues were cut into 10-μm sections and incubated with the primary antibodies overnight at 4°C. For immunohistochemistry, brain sections were incubated with a horseradish peroxidase--conjugated secondary antibody for 1 h at room temperature. Signals were detected using a DAB substrate kit, and nuclei were counterstained with hematoxylin. For immunofluorescence, brain sections were incubated with a fluorescent-conjugated secondary antibody for 1 h at room temperature. Nuclei were counterstained with Hoechst 33342.

### γ-H2AX assay {#S23}

Cells were placed in chamber slides and covered with laminin/poly-L-ornithine-coated coverslips 24 h prior to treatments. At the indicated times, the cells were fixed in 4% paraformaldehyde, permeabilized with 0.5% Triton-X/PBS, and stained with an anti-γ-H2AX antibody (1:500) according to standard protocols and anti-rabbit conjugated Alexa 594 secondary antibody was used to detect the foci. The foci in at least 25 nuclei for each group were counted.

### Single cell motility assay {#S24}

Single cell motility under guided migration conditions on microtextured polydimethylsiloxane (PDMS) surfaces was monitored for approximately 20 h ([@R23]; [@R59]). The PDMS surfaces were fabricated using a simple replica-molding process with a photolithographically fabricated Si master mold ([@R23]). Briefly, a mixture of PDMS and curing agent at a 10:1 ratio was spin-coated onto a patterned Si wafer at 300-500 rpm for 1 min. The PDMS was allowed to cure at room temperature for \> 48 h and then removed from the master mold. Circular, 12-mm-diameter specimens of patterned PDMS were cut out and affixed to the bottoms of 12-well plates prior to sterilization with 70% ethanol. The cells were then plated and allowed to adhere and spread for a few hours on the patterned PDMS surfaces in serum-containing, heparin-free medium. Cell motility was then traced using time-lapse microscopy with an Eclipse Ti-E microscope (Nikon) fitted with a stage cell culture chamber (Okolab). Images were collected every 10 min, and quantitative cell migration analysis was performed through image processing using the manual tracker plugin in Fiji.

### Nanochannel-based electroporation-based transfection of molecular beacon probes {#S25}

Three-dimensional nanochannel-based electroporation (NEP) chips were fabricated on silicon wafers using semiconductor cleanroom techniques that included KOH etching, which reduces the wafer thickness to 250 μm; ultraviolet photolithography (projection/contact photolithography), which generates an array of nanochannels (with diameters of 300-500 nm) with 25-μm spacing; and deep reactive ion-etch for high-aspect-ratio (\> 40) nanochannel etching ([@R9]; [@R14]; [@R82]). Before the cell experiment, the NEP chips were sterilized with 70% ethanol and overnight exposure to ultraviolet light. Concentrations of CD133-MB (200 nM) and CD109-MB (100 nM), optimized for monitoring CD133 and CD109 mRNA levels via fluorescence imaging, were pre-mixed, and then approximately 100 μL of mixed MB solution was pipetted into the electroporation reagent reservoir. Irradiated single cells (\~100,000 cells/ ml in suspension) were placed onto an engineered array of nanochannels that focused the porating electric field (electroporation voltage, 100 V; pulse duration, 10 ms; 2 pulses) to a corresponding area on the cell membrane, leading to the uniform and benign NEP-based transfection of irradiated cells with MBs. Cells were transferred from the incubator to an on-stage cell culture chamber (Okolab) 1 h after transfection. Time-lapse *in vitro* live cell imaging was then performed using an inverted microscope system (Eclipse Ti-E, Nikon) equipped with a motorized stage and electron multiplying charge-coupled device camera (Evolve, Photometrics).

### Luciferase assay {#S26}

For the luciferase assay, GSCs were transfected with 8x GTIIC-luciferase and pRL-TK Renilla as the luciferase control reporter vector using Lipofectamine 2000. Assays were performed 36 h after transfection, and the activities of firefly luciferase and Renilla luciferase were quantified using the dual reporter luciferase assay. The firefly luciferase signals were normalized to those of the internal Renilla luciferase control. Transfections were done in triplicate in 2 independent experiments.

### Chromatin immunoprecipitation {#S27}

A chromatin immunoprecipitation (ChIP) assay was performed after cross-linking cells using formaldehyde. DNA was sonicated using a GE130 ultrasonic processor (Sorvall) for 3 cycles of 15 pulses each at 50% power with a 1-min interval between cycles. The sonicated DNA was then centrifuged at 13,500 rpm at 4°C. The supernatant from 100,000 cells was used for each ChIP assay using the MAGnify ChIP system (Invitrogen). Two micrograms of the mouse IgG C/EBP-β was used per ChIP. Immunoprecipitated DNA was analyzed by Taqman PCR, and Ct values were used to calculate the percentage of input enrichment. Three set of primers for C/EBP-β and STAT-3 have been designed on the human CD109 promoter sequence browsed from pubmed, using Primer3Plus software program and following the guidelines reported in the MAGnify ChIP system.

### Cell cycle analysis {#S28}

GSCs were pelleted by centrifugation and dissociated with Accutase (Sigma) using a 1 mL sterile pipette. Cells were then washed with PBS to remove Accutase, resuspended in 1 mL of cold PBS, and fixed with 2 mL of 100% pre-cooled ethanol. After fixation overnight, cells were resuspended and washed with fluorescence-activated cell sorting (FACS) buffer (0.5% bovine serum albumin and 25 mM ethylenediaminetetraacetic acid in PBS). Cell pellets were then re-suspended in 800 μl of FACS buffer containing 20 μl of RNase A (10 mg/ml) and incubated at 37°C for 30 min. After incubation, the cells were treated with 50 μl of propidium iodide (500 g/ml); cell cycle analysis was performed using a FACS BD Accuri C6 plus flow cytometer (BD Biosciences), and propidium iodide incorporation was estimated using the BD Accuri C6 plus software program. For each measurement, at least 10,000 cells were acquired. Cell cycle analysis was performed using the Flowjo software program (Tree Star Inc.).

### Data and software used {#S29}

For the comparison of the gene expression signatures in the tumor core and invading regions, supervised clustering of RNA-seq data from the Ivy Glioblastoma Atlas Project (GEO: GSE107559). Tumors were classified as proneural (PN), mesenchymal (MES), or classic (CL) using gene signatures ([@R73]).

RNA-seq and Agilent microarray data were downloaded from the Genomic Data Commons for the GBM and low grade glioma datasets (<https://portal.gdc.cancer.gov/>). Data were processed using R and Bioconductor ([@R4]). Normal tissue, and primary and recurrent tumor determination was derived from the TCGA sample code, and GBM subtype was determined using previously defined subtype signatures ([@R73]).

Heatmap and clustering were performed with Cluster 3.0 software using the Pearson correlation coefficient (<http://bonsai.hgc.jp/~mdehoon/software/cluster/>).The microarray data for sh-NT versus sh-CD109 have been deposited (GEO: GSE113149). GSEA was performed using web-based tools (<http://software.broadinstitute.org/gsea/>) to analyze the enrichment of signaling target genes. The DNA binding motif analyses was performed using publicly available software (LASAGNA, ConTra V2, and TRAP)([@R11]; [@R42]; [@R70]).

### *Drosophila* samples, immunofluorescence and imaging {#S30}

All *Drosophila* stocks and crosses were maintained at 25°C.

Immunohistochemistry was done using a protocol described previously ([@R72]). The primary antibodies were rabbit anti-Yki (1:400; a gift from K. Irvine), mouse anti-DIAP1 (1:100; a gift from B. Hay), rabbit anti-b-gal (1:100; Invitrogen), and rabbit anti-dMyc (1:100; Santa Cruz Biotechnology). The secondary antibodies were donkey anti-mouse or anti-rabbit IgG conjugated to Cy3 (1:200; Jackson ImmunoResearch). Samples were imaged using an Olympus Fluoview 1000 confocal microscope, and the images were edited using Adobe Photoshop CS6.0. Brain lobe size in pixels was measured using the histogram function of Adobe Photoshop CS6.0. Data are presented as the means and standard deviations calculated for each sample. A 2-tailed t test performed with Excel 2013 was used to determine whether the observed differences were significant (p \< 0.05).

QUANTIFICATION AND STATISTICAL ANALYSIS {#S31}
---------------------------------------

For most experiments, p values were calculated in Microsoft Excel using a two-tailed Student t test which can be found in the individual figures and figure legends. 1-way ANOVA was also used for multiple comparisons using SPSS 17.0 software (IBM). *p* values less than 0.05 were considered significant. In one case ([Figure 6D](#F6){ref-type="fig"}), the difference in the expression of *ANKRD1* did not meet statistical significance. Cell culture experiments were performed with an n \> 3 and are indicated in the figure legends. *In vivo* studies with mouse model have been performed using n = 5 mice/condition as indicated in the figure legends. Error bars in graphs are defined in the figure legends and represent the mean ± SD (standard deviation). Log-rank analysis was used to assess differences in survival rates/durations. Although the influence of sex on outcomes were not specifically analyzed, mice of either sex were randomized into each experimental group.

The Kaplan-Meier method was used to analyze mouse and human survival data using the Graph Pad Prism software program. For the comparison of *CD109* and *CD133* expression in matched primary and recurrent GBMs, RNA-seq data from previously published datasets ([@R36]) were processed and analyzed. Among the 840 marker genes ([@R73]), 787 annotated genes were used to classify the GBM subtypes of 46 longitudinal samples. Delta values of these genes were calculated using *CD133* and *CD109* expression in longitudinal samples (delta value = rpkm in recurrent tumor-rpkm in primary tumor). For the gene set enrichment analysis (GSEA), a T score (adjusted from the t test) for each gene between primary and recurrent tumors was obtained and used to create an .rnk file to rank all genes based on their scores. The generated .rnk file was then used as an input for GSEA Preranked software. In addition, single-sample GSEA was applied to determine the enrichment score of the MES gene set (216 genes) of 46 longitudinal samples.

For the comparison of PN and MES signatures in GSCs and the comparison of these signatures with those of clinical GBM samples, Affymetrix Expression arrays were used for GSC signatures and compared with previously published GSE67089 datasets in the NCMI Gene Expression Omnibus ([@R48]). We selected the top 2,838 differentially expressed genes (1,347 upregulated and 1,419 downregulated genes with expression level changes of at least 3-fold in at least 5 of 9 total conditions) as features that represent GBM tumors from TCGA and performed hierarchical clustering analyses. For the comparison of parental and irradiated PN cells and the comparison of shNT- and shCD109-infected cells gene expression microarray data were preprocessed and normalized with Affymetrix Expression Console software (V1.2.1) using the RNA sketch method.

For the comparison of *CD109* expression in human GBMs, RNA-seq and Agilent data for the GBM and low-grade glioma datasets were downloaded from the Genomic Data Commons (<https://portal.gdc.cancer.gov/>). Data were processed using R and Bioconductor (<http://www.R-project.org>). For microarray of GSCs, differentially expressed genes were identified using fold change ([@R48], GSE67089). Double-clustering (independently clustering samples and genes) was performed on all 5,475 differentially expressed genes and 27 samples using hclust function of the R statistical software package, in which Euclidean distance and average linkage were used as similarity metrics for the clustering method. Differentially expressed genes were further compared to all pathways listed in KEGG, and an enrichment *p-value* for each pathway was calculated using the Fisher exact test. Pathways that had a *p-value* of less than 0.05 were considered significantly enriched.
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![Discovery of Mutually Exclusive Populations of Tumor-Initiating Cells in GBM\
(A) Heatmap depicting PN (top) and MES (bottom) gene expression in different GBM regions. See also [Figure S1A](#SD1){ref-type="supplementary-material"}.\
(B) Magnetic resonance imaging of the macroscopic tumor (left) and H&E staining (right; scale bar, 120 μm) of GBM tissue. The tumor contains 3 areas: a central core (1), an enhancing periphery (2), and an invading edge (3).\
(C) qPCR analysis for genes in the central core (blue) or edge (orange).\
(D) IHC for CD109 (brown) and OLIG2 (red). Scale bars, 60 μm (top) and 20 μm (bottom).\
(E) Flow cytometry staining of CD109 in freshly dissociated tumor cells (left). qPCR analysis for genes in sorted CD109^−^ cells (blue) and CD109^+^ cells (red; right). \*\*p \< 0.01, \*\*\*p \< 0.001, and \*\*\*\*p \< 0.0001.\
(F) qPCR analysis of *CD133* expression in a freshly dissociated xenograft derived from a patient sample (GBM1066). \*\*\*\*p \< 0.0001.\
(G) Lineage hierarchy in sorting of CD109^+^ and CD109^−/low^ populations from MES GSC83 cells.\
(H) Western blot analysis of CD109 and ALDH1A3 in CD109^+^ and CD109^−/low^ cells.\
(I) Table showing number of mice bearing tumors injected with either CD109^+^ or CD109^−/low^ sorted cells using freshly dissociated cells from patients GBM1020 or GBM1010 or from MES GSC83.\
(J) H&E staining of xenograft tumors derived from CD109^+^ (left) and CD109^−/low^ (right) cells at 2 different magnifications.](nihms-1521503-f0001){#F1}

![CD109 Enrichment Is Associated with the MES Subtype and Worse Prognosis\
(A) CD109 expression for normal brain, low-grade glioma (LGG), primary GBM, and recurrent GBM (rGBM) from TCGA datasets is shown. Left: normal versus LGG, p = 0.03572; normal versus GBM, p = 3.925e--05; LGG versus GBM, p = 8.529e--10. Center: normal versus LGG, p = 0.03572; normal versus GBM, p = 5.605e--05; normal versus rGBM, p = 0.0004907; LGG versus GBM, p = 2.992e--08; LGG versus rGBM, p = 0.002994; GBM versus rGBM, p = 0.08103. Right: normal versus LGG, p = 0.03002; normal versus rLGG, p = 0.577; normal versus GBM, p = 5.605e--05; normal versus rGBM, p = 0.0004907; LGG versus GBM, p = 7.54e--08; rLGG versus GBM, p = 0.0003432; LGG versus rGBM, p = 0.003294; rLGG versus rGBM, p = 0.0003273; GBM versus rGBM, p = 0.08103.\
(B) CD109 expression in TCGA datasets grouped by GBM subtype. CL versus MES, p \< 2.2e--16; CL versus PN, p = 1.239e--05; MES versus PN, p \< 2.2e--16.\
(C) A total of 46 longitudinal samples categorized into groups based on alterations in *CD133* and *CD109* expression. The subtype of each recurrent tumor is shown in the box.\
(D) A total of 46 paired samples classified into 3 groups according tothe recurrent tumor's subtype (MES, CL, or PN). Each dot represents a patient; primary and recurrent samples are connected by a line. MES, p = 0.014; CL and PN, p = NS.\
(E) Kaplan-Meier survival curves for patients with differential *CD133* and *CD109* expression (top) and with differential *CD109* expression only (bottom) from the Rembrandt dataset.\
(F) Overall survival of 46 high-grade glioma (HGG) patients grouped according to low (blue), mild (green), and high (red) CD109 expression by immunostaining. Scale bars, 200 --m. p \< 0.0001. See also Figures S2F and S2G.](nihms-1521503-f0002){#F2}

![IR Induces and Enriches CD109^+^ Cells\
(A) Principal-component analysis of gene expression profiles stratifies PN and MES GSCs. PN GSCs from the same patient are indicated by the same color and shape. There are 2 distinct clusters: one consists of untreated PN GSCs, and the other consists of MES GSCs and the corresponding irradiated PN GSCs. See also [Figure S2A](#SD1){ref-type="supplementary-material"}.\
(B) Heatmap showing the 2,838 most differentially expressed genes between PN and MES GSCs and their ability to segregate TCGA PN or MES subtypes.\
(C) Dot plot showing the log ratio of CD gene expression in untreated GSC157 (PN) versus irradiated GSC157 (IR-PN) cells. On the x axis, genes farther to the left have a higher expression in irradiated PN GSCs, whereas genes farther to the right have a higher expression in untreated PN GSCs.\
(D) Western blotting showing CD109 expression in PN and MES GSCs.\
(E) qPCR analysis for *CD133* and *CD109* expression in untreated GSC157 (PN) and irradiated GSC157 (IR-PN) cells at 24, 48, and 120 h. \*\*\*\*p \< 0.0001.\
(F) Fluorescence images of CD133^−^ (left) and CD133^+^ (right) GSC157 cells transfected with *CD109* molecular beacons (red: CY5) 24 h after radiation (n = 5.0 × 10^5^). Top scale bar, 500 μM; bottom scale bar, 100 μM.\
(G) Fluorescence images of GSC84 cells after transfection with *CD133* (green: FAM) and *CD109* (red) molecular beacons at the indicated times. Scale bars, 10 μM.\
(H) Scatterplots showing staining of CD109 in various GSCs.\
(I) Extreme limiting dilution analysis revealed the sphere formation frequencies of untreated GSC157 and GSC157/R cells. \*\*\*p \< 0.001.\
(J) Single-cell motility of untreated GSC157 cells and GSC157/R cells 3 months after IR. p \< 0.001. See also [Figure S3F](#SD1){ref-type="supplementary-material"}.\
(K) H&E staining (top; scale bars, 500 μm \[left\], 100 μm \[right\]) and immunofluorescence staining for CD44 or human-specific nuclear antigen (\[HSNA\] bottom; scale bars, 100 μm \[right\]) in mouse brains harboring tumors implanted with untreated GSC157 cells (left) or GSC157/R cells 3 months after IR (right; n = 5 per group). HSNA staining demonstrates the hypercellularity of GSC157/R xenografts. Scale bars, 200 μm and 50 μm for top and bottom CD109, respectively.\
(L) Table showing number of mice bearing tumors injected with either CD109^+^ or CD109^−/low^, using GSC157/R cells 3 months post IR.](nihms-1521503-f0003){#F3}

![CD109 Is Regulated by C/EBP-β in Response to IR in CD133^high^/PN GSCs\
(A) *CD109* expression in GSC11 (left) and GSC23 (right) cells upon IR(12 Gy) and TNF-α treatment (10 μM). The bars represent the means ± SDs of 3 independent experiments. \*\*p \< 0.005 and \*\*\*p \< 0.0005.\
(B) Predicted binding sites for STAT3 and C/EBP-β at −200 and −75 bp, respectively, from the CD109 transcription start site.\
(C) *STAT3* (white bar) and *CEBPB* (black bar) mRNA expression 0,6, and 24 h after IR(12 Gy) in GSC11 (left) and GSC23 (right) cells. The bars indicate the means of 3 independent experiments. \*p \< 0.05 and \*\*p \< 0.005.\
(D) *CD109* transcript expression in GSC11 (left) and GSC23 (right) cells transfected with control siRNA or with siRNA against *CEBPB* or *STAT3* (right) before and after IR (12 Gy). The graph shows the results of 3 independent experiments. \*\*p \< 0.005.\
(E) Chromatin immunoprecipitation assay reveals the fold enrichment of C/EBP-β binding on the CD109 promoter relative to immunoglobulin G (IgG) in GSC11 cells; GSC11 cells 24 h after IR (12 Gy) or TNF-α treatment (10 μM); and GSC20 cells. The bar indicates the mean of 2 independent experiments in which the samples were run in triplicate. \*\*\*p \< 0.0005.\
(F) Gene Ontology analysis of gene expression profiles reveals the top 4 enrichment categories for irradiated cells.\
(G) *CEBPB* expression in untreated GSC157 cells and GSC157/R cells 3 months after exposure to IR.](nihms-1521503-f0004){#F4}

![CD109 Plays an Essential Role in Clonogenicity, Tumor Initiation, and Radioresistance in GBM\
(A) Western blotting of CD109 in GSC267 cells infected with shNT or with shCD109--1 and shCD109--2.\
(B) Neurosphere formation efficiency in GSC185A clones. \*\*\*p \< 0.001. See also [Figure S5A](#SD1){ref-type="supplementary-material"}.\
(C) Representative H&E staining of xenograft tumor derived from GSC267 cells stably transduced with shNT or shCD109. Arrows (right) show the injection site. The inset image (left) shows the core tumor area.\
(D) Cell-cycle analysis of irradiated GSCs (6 Gy). The percentage of cells in the G2/M phase is indicated within each cell-cycle plot.\
(E) Immunofluorescence images of γ-H2AX foci in shNT and shCD109 cells (left). Bars indicate the number of foci 24 h after IR. Black bars represent shNT; gray bars represent shCD109. Error bars indicate SEMs. \*p \< 0.05 and \*\*p \< 0.005.\
(F) Annexin V and propidium iodide staining in GSC267 clones. The results are representative of 3 independent experiments.\
(G) Kaplan-Meier survival curves for mice implanted with GSC20 cells with or without fractioned intracranial radiation (2.5 Gy, Å \~4).](nihms-1521503-f0005){#F5}

![Evolutionarily Conserved Regulation of TAP/TAZ Activity by CD109 in Gliomagenesis\
(A) Scatterplot showing differential gene expression between GSCs infected with shNT or shCD109. Values indicate RNA-normalized intensities. Upregulated (red) and downregulated (blue) genes are included. The top genes related to the YAP/TAZ signature are labeled.\
(B) Gene set enrichment analysis (GSEA) reveals a significant correlation of CD109 with YAP/TAZ pathway signatures.\
(C) Relative luciferase activity in shNT- or shCD109-transduced GSC20 cells transfected with 8xGTIIC-Luc reporter. Data are the means ± SDs of 3 independent experiments. \*\*p \< 0.005.\
(D) qPCR analysis of genes in GSC20 and GSC28 cells infected with shNT or shCD109. \*p \< 0.05, \*\*p \< 0.005. NS, not significant.\
(E) Western blotting of total TAZ in GSC20 and GSC28 cells infected with shNT or shCD109. Actin was used as the loading control.\
(F) Western blotting of nuclear TAZ in GSC20 cells infected with shNT or shCD109 (right). Lamin B was used as the loading control.\
(G) Correlation of *CD109* expression with *YAP* (left; adjusted *R*^2^, 0.3172; p \< 2.2e--16) and *TAZ* (right; adjusted *R*^2^, 0.3135; p \< 2.2e--16) in TCGA Agilent gene expression datasets for glioma.\
(H) Yki expression (red, gray) in the larval CNS of the indicated genotypes. Glial cells are marked by GFP (green). Panels show comparison of DIAP1 expression in wild-type (*repo \> GFP*), *repo* \> *GFP, Pten^RNAi^, Ras^V12^, repo* \> *GFP, Pten^RNAi^, Ras^V12^, Tep1^RNAi^* and *repo* \> *GFP*, and *Tep1*^*RNAi*^ larval brains.](nihms-1521503-f0006){#F6}

###### 

KEY RESOURCES TABLE

  REAGENT or RESOURCE                                                                                                              SOURCE                                 IDENTIFIER
  -------------------------------------------------------------------------------------------------------------------------------- -------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Antibodies                                                                                                                                                              
  Human PE-conjugated anti-CD109                                                                                                   R&D                                    FAB4385P; RRID: AB_10643402
  Human APC-conjugated anti-CD133                                                                                                  Miltenyi Biotec                        Cat\# 130-090-826; RRID: AB_244340
  Mouse IgG1 Isotype control (clone 11711)                                                                                         R&D                                    Cat\# MAB002; RRID: AB_357344
  CD109                                                                                                                            Santa Cruz                             Cat\# Sc-271085; RRID: AB_10610041
  ALDH1A3                                                                                                                          Sigma                                  Cat\# ABN427; RRID: AB_2783547
  CD44                                                                                                                             Cell Signaling                         Cat\# 3578; RRID: AB_2076463
  p21                                                                                                                              Santa Cruz                             Cat\# 56335; RRID: AB_785023
  TAZ                                                                                                                              Cell Signaling                         Cat\# V386; RRID: AB_1904158
  YAP                                                                                                                              Cell Signaling                         Cat\# D24E4; RRID: AB_10950494
  p-YAP~127~                                                                                                                       Cell Signaling                         Cat\# D9W21; RRID: AB_2650553
  C/EBP-β                                                                                                                          Santa Cruz                             Cat\# sc-150; RRID: AB_2260363
  β-actin                                                                                                                          Santa Cruz                             Cat\# 477758; RRID: AB_626632
  GAPDH                                                                                                                            Abcam                                  Cat\# ab9483; RRID: AB_307273
  N-cadherin                                                                                                                       BD Biosciences                         Cat\# 610920; RRID: AB_2077527
  Vimentin                                                                                                                         DAKO                                   Cat\# M0725; RRID: AB_10015203
  OLIG2                                                                                                                            Millipore                              Cat\# AB9610; RRID: AB_570666
  Human specific nuclear antigen                                                                                                   Millipore                              Cat\# MAB1273; RRID: AB_94052
  rabbit anti-Yki                                                                                                                  a gift from K. Irvine                  N/A
  mouse anti-DIAP1                                                                                                                 a gift from B. Hay                     N/A
  rabbit anti-β-gal                                                                                                                Invitrogen                             Cat\# A-5790; RRID: AB_2536194
  anti-Myc                                                                                                                         Santa Cruz Biotechnology               Cat\# SC-40; RRID: AB_627268
  donkey anti-mouse or anti-rabbit IgG conjugated to Cy3                                                                           Jackson ImmunoResearch                 Cat\# 715-165-150; 711-165-152; RRID:2340813, RRID:2307443
  anti-γ-H2AX                                                                                                                      R&D system                             Cat\# MAB3406; RRID: AB_2114988
  IgG C/EBP-γ                                                                                                                      Abcam                                  Cat \# ab15050; RRID: AB_301598
  Bacterial and virus strains                                                                                                                                             
  Adenovirus RFP                                                                                                                   Vector Biolabs                         Cat\# 1660
  Adenovirus IκB-SR                                                                                                                Vector Biolabs                         N/A
  Chemicals, Peptides, and Recombinant Proteins                                                                                                                           
  TNFα                                                                                                                             Sigma Aldrich                          Cat\# SRP3177
  Hoechst 33342                                                                                                                    Sigma                                  Cat\# 14533
  Propidium Iodide                                                                                                                 Sigma                                  Cat\# P4170
  Critical Commercial Assays                                                                                                                                              
  Proteinase inhibitor                                                                                                             Roche                                  Cat\# P8340
  Lipofectamine 2000                                                                                                               Invitrogen                             Cat\# 11668019
  RNeasy Mini kit                                                                                                                  QIAGEN                                 Cat\# 74104
  Syber Green master mix                                                                                                           Applied Biosystems                     Cat\# 4385612
  Accutase                                                                                                                         Sigma                                  Cat\# A6964
  1 × Taqman Universal PCR Master Mix                                                                                              Applied Biosystems                     Cat\# 4369016
  Lenti-X concentrator                                                                                                             Clontech                               Cat\# 631231
  Calcium phosphate transfection kit                                                                                               Clontech                               Cat\# 631312
  iScript Reverse Transcription Supermix                                                                                           Biorad                                 Cat\# 17008840
  Dual reporter luciferase assay                                                                                                   Promega                                Cat\# E1910
  MAGnify ChIP system                                                                                                              Invitrogen                             Cat\# 492024
  Experimental Models: Cell Lines                                                                                                                                         
  GSC157                                                                                                                           Established from GBM patient samples   [@R5]; [@R19]; [@R25]; [@R48]; [@R55]
  GSC84                                                                                                                            Established from GBM patient samples   [@R5]; [@R19]; [@R25]; [@R48]; [@R55]
  GSC185A                                                                                                                          Established from GBM patient samples   [@R5]; [@R19]; [@R25]; [@R48]; [@R55]
  GSC83                                                                                                                            Established from GBM patient samples   [@R5]; [@R19]; [@R25]; [@R48]; [@R55]
  GSC267                                                                                                                           Established from GBM patient samples   [@R5]; [@R19]; [@R25]; [@R48]; [@R55]
  GSC11                                                                                                                            Established from GBM patient samples   [@R5]; [@R19]; [@R25]; [@R48]; [@R55]
  GSC20                                                                                                                            Established from GBM patient samples   [@R5]; [@R19]; [@R25]; [@R48]; [@R55]
  GSC28                                                                                                                            Established from GBM patient samples   [@R5]; [@R19]; [@R25]; [@R48]; [@R55]
  GSC23                                                                                                                            Established from GBM patient samples   [@R5]; [@R19]; [@R25]; [@R48]; [@R55]
  GSC1010                                                                                                                          Established from GBM patient samples   [@R5]; [@R19]; [@R25]; [@R48]; [@R55]
  GSC1020                                                                                                                          Established from GBM patient samples   [@R5]; [@R19]; [@R25]; [@R48]; [@R55]
  GSC1071                                                                                                                          Established from GBM patient samples   [@R5]; [@R19]; [@R25]; [@R48]; [@R55]
  GSC1079                                                                                                                          Established from GBM patient samples   [@R5]; [@R19]; [@R25]; [@R48]; [@R55]
  293FT                                                                                                                            ATCC                                   CRL-1573
  Experimental Models: Organisms/Strains                                                                                                                                  
  Mouse: Foxn1^nu^                                                                                                                 ERO                                    N/A
  *Drosophila: repoGAL4 UAS-GFP/TM3*                                                                                               Flybase                                N/A
  *Drosophila*: Sb                                                                                                                 Flybase                                [@R75]
  *Drosophila: UAS-pten^RNAi^*                                                                                                     Flybase                                BL\# 8548
  *Drosophila: UAS-Ras^V12^*                                                                                                       Flybase                                [@R35]
  *Drosophila: UAS-Tep1^RNAi^*                                                                                                     Flybase                                BL\#32856
  *Drosophila*: Tep1^MI04262^                                                                                                      Flybase                                BL\# 37420
  *Drosophila*: UAS-Tep3^RNAi^                                                                                                     Flybase                                BL\# 56020
  *Drosophila*: Tep2^MI01299-GFSTF.2^                                                                                              Flybase                                BL\#59402
  Oligonucleotides                                                                                                                                                        
  Refer to [Table S3](#SD2){ref-type="supplementary-material"} for RT-PCR primers                                                  This paper                             N/A
  Refer to [Table S4](#SD3){ref-type="supplementary-material"} for Chip primers                                                    This paper                             N/A
  siRNA targeting sequences against STAT3 and C/EBP-β                                                                              Dharmacon                              Cat \# E-003544-00-0005; E-006423-00-0005
  CD109 (CD109 -- MB): 5′-Cy5-CGCGATC-\[+A\]TA\[+T\]AG\[+G\]CT\[+G\]TA\[+A\]GT\[+G\]TT\[+A\]CT\[+G\]GA-GATCGCG-BHQ3-3′             Sigma-Aldrich                          N/A
  (CD133 -- MB): 5′-FAM-CGCGATC-\[+T\]CA\[+T\]CC\[+T\]TG\[+A\]AT\[+A\]GT\[+G\]AT\[+G\]GAC-GATCGCG-BHQ1-3′                          Sigma-Aldrich                          N/A
  (scramble MBs) targeting cel-miR-39: 5′-Cy5-CGCGATC\[+C\]AA\[+G\]CU\[+G\]AU\[+U\]UA\[+C\]AC\[+C\]CG\[+G\]UGA-GATCGCG-BHQ3-3′;    Sigma-Aldrich                          N/A
  (scramble MBs) targeting cel-miR-39: 5^′^-FAM-CGCGATC\[+C\]AA\[+G\]CU\[+G\]AU\[+U\]UA\[+C\]AC\[+C\]CG\[+G\]UGA-GATCGCG-BHQ1-3′   Sigma-Aldrich                          N/A
  Recombinant DNA                                                                                                                                                         
  8xGTIIC-luciferase                                                                                                               [@R20]                                 Cat\# 34615
  pRL-TK Renilla                                                                                                                   This paper                             
  pLKO.1 shCD109                                                                                                                   Sigma                                  Cat\# SHCLND-NM_133493
  pLKO.1 shscramble                                                                                                                Sigma                                  Cat\# SHC007
  pBABE vector                                                                                                                     [@R4]                                  Donated by Dr Kun-Lian Guan
  pBABE TAZ                                                                                                                        [@R4]                                  Donated by Dr Kun-Lian Guan
  pBABE 4SA                                                                                                                        [@R4]                                  Donated by Dr Kun-Lian Guan
  pBABE 4SA-S51A                                                                                                                   [@R4]                                  Donated by Dr Kun-Lian Guan
  Software and Algorithms                                                                                                                                                 
  ELDA                                                                                                                             web                                    <http://bioinf.wehi.edu.au/software/elda/>
  SPSS 17.0 software                                                                                                               IBM                                    <https://www.ibm.com/analytics/spss-statistics-software>
  Viia7 Real-Time PCR                                                                                                              Applied Biosystem                      <https://www.thermofisher.com/us/en/home/life-science/pcr/real-time-pcr/real-time-pcr-instruments/viia-7-real-time-pcr-system.html>
  BD Accuri C6 plus                                                                                                                BD Biosciences                         <http://www.bdbiosciences.com/us/instruments/research/cell-analyzers/bd-accuri/m/1294932/overview>
  Flowjo software program                                                                                                          Tree Star                              <https://www.flowjo.com/>
  Other                                                                                                                                                                   
  Nanodrop 2000 UV-Vis Spectrophotometer                                                                                           Thermo Scientific                      <https://www.thermofisher.com/order/catalog/product/ND-2000>
  Primer3Plus                                                                                                                      web                                    <https://primer3plus.com/cgi-bin/dev/primer3plus.cgi>
  LASAGNA                                                                                                                          web                                    <https://academic.oup.com/bioinformatics/article/30/13/1923/2422166>
  TRAP                                                                                                                             web                                    <http://trap.molgen.mpg.de/>
  Con Tra V2                                                                                                                       web                                    <http://bioit2.irc.ugent.be/contra/v3/#/step/1>
  Affymetrix Expression Console software (V1.2.1)                                                                                  ThermoFisher Scientific                <https://www.thermofisher.com/us/en/home/life-science/microarray-analysis/microarray-analysis-instruments-software-services/microarray-analysis-software/affymetrix-transcriptome-analysis-console-software.html>
  Cluster 3.0                                                                                                                      web                                    <https://www.geo.vu.nl/~huik/cluster.htm>

###### Highlights

-   Distinct types of GSCs exist in the GBM core versus the invasive edge

-   Gain of CD109 in tumor cells occurs at the invasive edge in response to IR

-   IR induced pro-inflammatory response transcriptionally regulates CD109 via C/EBP-β

-   CD109 drives oncogenic signaling through the YAP/TAZ pathway
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